Patents Assigned to ConjuChem Biotechnologies Inc.
-
Publication number: 20110166061Abstract: The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: April 26, 2010Publication date: July 7, 2011Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra De Meyer
-
Patent number: 7741453Abstract: The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: GrantFiled: May 31, 2002Date of Patent: June 22, 2010Assignee: Conjuchem Biotechnologies, Inc.Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer
-
Patent number: 7741286Abstract: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.Type: GrantFiled: February 8, 2006Date of Patent: June 22, 2010Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau
-
Patent number: 7737251Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.Type: GrantFiled: December 23, 2005Date of Patent: June 15, 2010Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
-
Publication number: 20090275506Abstract: This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardiovascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF.Type: ApplicationFiled: October 17, 2008Publication date: November 5, 2009Applicant: Conjuchem Biotechnologies, Inc.Inventors: Peter BAKIS, Dominique P. Bridon, Julie Carette, France LeClaire, Roger Leger, Martin Robitaille
-
Patent number: 7608271Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: GrantFiled: September 24, 2004Date of Patent: October 27, 2009Assignee: Conjuchem Biotechnologies Inc.Inventors: Dominique P. Bridon, Robert S. Dufresne, Nisssab Boudjellab, Martin Robitaille, Peter G. Milner
-
Patent number: 7601691Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: GrantFiled: February 25, 2005Date of Patent: October 13, 2009Assignee: Conjuchem Biotechnologies Inc.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Patent number: 7582301Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: GrantFiled: May 17, 2000Date of Patent: September 1, 2009Assignee: Conjuchem Biotechnologies, Inc.Inventors: Dominique P. Bridon, Robert P. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
-
Publication number: 20090099074Abstract: The present disclosure relates to a conjugate comprising a PYY peptide or a functional derivative thereof which is coupled to a reactive group. Such a reactive group reacts with albumin so as to form a stable covalent bond therewith. The disclosure further provides methods of reducing water or food intake and reducing food intake between meals by administering such conjugates.Type: ApplicationFiled: December 27, 2007Publication date: April 16, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES INC.Inventors: Dominique P. Bridon, Karen Thibaudeau, Alastair Ferguson, Denis Richard
-
Publication number: 20090088377Abstract: This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: May 16, 2008Publication date: April 2, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Omar Quraishi, Martin Robitaille, Dominique P. Bridon
-
Publication number: 20090054332Abstract: The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides.Type: ApplicationFiled: June 21, 2008Publication date: February 26, 2009Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Jean-Philippe Estradier, Martin Robitaille, Karen Thibaudeau, Dominique P. Bridon, Xicai Huang, Omar Quraishi, Nathalie Bousquet-Gagnon
-
Publication number: 20080312415Abstract: This invention relates to enfuvirtide peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to enfuvirtide derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: ApplicationFiled: December 26, 2007Publication date: December 18, 2008Applicant: ConjuChem Biotechnologies Inc.Inventor: Omar Quraishi
-
Publication number: 20080199483Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: ApplicationFiled: October 23, 2007Publication date: August 21, 2008Applicant: CONJUCHEM BIOTECHNOLOGIES INC.,Inventors: Dominique P. Bridon, Robert S. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
-
Publication number: 20080194486Abstract: The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.Type: ApplicationFiled: October 24, 2007Publication date: August 14, 2008Applicant: CONJUCHEM BIOTECHNOLOGIES, INC.Inventors: Dominique P. Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G. Milner
-
Publication number: 20080176794Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.Type: ApplicationFiled: October 23, 2007Publication date: July 24, 2008Applicant: CONJUCHEM BIOTECHNOLOGIES INC.Inventors: Dominique P. Bridon, Robert S. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
-
Patent number: 7307148Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.Type: GrantFiled: April 22, 2005Date of Patent: December 11, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
-
Patent number: 7268113Abstract: This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.Type: GrantFiled: February 1, 2002Date of Patent: September 11, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Lucie Jetté, Corinne Benquet
-
Patent number: 7256253Abstract: A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a blood component to form a stable covalent bond. The reactive group is attached at a position along the peptidic sequence that provides, when conjugated to a blood component, a higher stability against peptidase degradation than the unconjugated secretin or derivative, and therefore an increased maintenance of the therapeutic activity compared to the unconjugated secretin or derivative. Such a compound is thus effective to provide a source of secretin having a high stability against peptidases. A method for synthesizing such a compound is also described.Type: GrantFiled: February 25, 2005Date of Patent: August 14, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 7166695Abstract: Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, respectively, and A is an affinity group comprising the sequence F-1-Y-E-E. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.Type: GrantFiled: September 2, 2004Date of Patent: January 23, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Alexander Krantz, Wolin Huang, Arthur M. Hanel, Darren L. Holmes, Dominique P. Bridon